在心血管疾病中针对内皮功能障碍的机制性见解和新兴治疗策略
Kyung-Sun Heo1, Lan Phuong Phan2, Nhi Thi Thao Le2
1Department of Pharmacology, Chungnam National University, College of Pharmacy, 99 Daehak-ro, Yuseong-gu, Daejeon, 34134, Republic of Korea. kheo@cnu.ac.kr.
内皮功能障碍通过破坏血管平衡来驱动心血管疾病. 表观遗传机制和新型疗法,如PCSK9抑制剂,为治疗和降低风险提供了新的途径.
科学领域:
- 心血管生物学 心血管生物学
- 血管医学 血管医学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 内皮功能障碍是心血管疾病 (CVD) 的核心,如动脉样硬化和高血压.
- 它涉及减少的氧化 (NO),氧化应激,炎症和内皮转移到介质细胞 (EndMT).
- 血液流动模式受到干扰会加剧内皮功能障碍.
研究的目的:
- 审查表观遗传机制在内皮功能障碍和动脉样硬化中的作用.
- 讨论心血管和代谢疾病中的内皮功能障碍.
- 突出新兴的内皮保护疗法.
主要方法:
- 文献综述侧重于内皮功能中的表观遗传调节 (DNA甲基化,基因质修饰,ncRNAs).
- 对切割应力对内皮细胞影响的分析.
- 对新药药理学剂的临床证据的审查.
主要成果:
- 表观遗传机制批判性地调节内皮对剪切应激的反应,影响功能障碍和动脉样硬化.
- 内皮功能障碍是心血管和代谢疾病的关键因素.
- 新兴药物在改善内皮功能和心血管结果方面表现有前途.
结论:
- 表观遗传调节是内皮功能障碍和动脉样硬化的重要因素.
- 针对内皮细胞保护的新型治疗策略对于管理心血管疾病至关重要.
- PCSK9抑制剂,GLP-1RA和SGLT2抑制剂在改善内皮健康和降低心血管风险方面表现出潜在的潜力.
更多相关视频
08:35Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
Published on: August 17, 2022
06:35Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test
Published on: April 27, 2016
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Mechanism of Angiogenesis
Cardiovascular Drugs: Classification based on Therapeutic Indications
Regulation of Angiogenesis and Blood Supply
